Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.74 and traded as low as $0.58. Vaxart shares last traded at $0.60, with a volume of 970,174 shares changing hands.

Vaxart Price Performance

The firm has a market cap of $134.67 million, a PE ratio of -1.44 and a beta of 0.62. The firm’s fifty day simple moving average is $0.70 and its two-hundred day simple moving average is $0.74.

Hedge Funds Weigh In On Vaxart

Several large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock valued at $2,160,000 after purchasing an additional 346,725 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after buying an additional 122,387 shares in the last quarter. Mesirow Financial Investment Management Inc. lifted its holdings in shares of Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after buying an additional 20,000 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Vaxart by 110.8% in the second quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after buying an additional 2,095,274 shares in the last quarter. Finally, Monaco Asset Management SAM purchased a new position in shares of Vaxart in the second quarter worth $402,000. Hedge funds and other institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.